News tagged with irinotecan
Related topics: chemotherapy
Irinotecan (Camptosar, Pfizer; Campto, Yakult Honsha) is a drug used for the treatment of cancer.
Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1. In chemical terms, it is a semisynthetic analogue of the natural alkaloid camptothecin.
Its main use is in colon cancer, in particular, in combination with other chemotherapy agents. This includes the regimen FOLFIRI, which consists of infusional 5-fluorouracil, leucovorin, and irinotecan.
Irinotecan received accelerated approval by the U.S. Food and Drug Administration (FDA) in 1996 and full approval in 1998. During development, it was known as CPT-11.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
(HealthDay)—For elderly patients with metastatic colorectal cancer (mCRC), scores on the Mini-Mental State Examination (MMSE) and Instrumental Activities of Daily Living (IADL) were predictive of severe ...
Cancer Mar 14, 2013 | not rated yet | 0
A University of Rhode Island researcher has discovered that the weight-loss drug orlistat, known by the brand names Xenical and Alli, inhibits a key enzyme that may lead to "severe toxicity of internal organs such as the ...
Medications Dec 10, 2012 | not rated yet | 0
A Cancer Research UK funded trial will offer new treatments for children and adults with a form of muscle cancer called rhabdomyosarcoma that has returned or does not respond to current treatments. ...
Cancer Oct 22, 2012 | not rated yet | 0
A new drug treatment could offer hope to patients with advanced colorectal cancer who were intolerant of or did not respond to standard treatments, according to an article published in the Lancet Oncology.
Cancer Aug 27, 2012 | not rated yet | 0
(HealthDay) -- Zaltrap (ziv-afilbercept) has been approved by the U.S. Food and Drug Administration in combination with a FOLFIRI chemotherapy regimen for adults with advanced metastatic (spreading) colorectal cancer, the ...
Medications Aug 04, 2012 | not rated yet | 0
(HealthDay) -- For patients with irinotecan-refractory metastatic colorectal cancer (CRC), dose escalation of cetuximab is well tolerated and may improve response and disease control rates, but patients experience ...
Cancer Jul 05, 2012 | not rated yet | 0
(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal ...
Cancer Jun 05, 2012 | not rated yet | 0
Researchers from the University of Zurich have found a cellular brake that protects cancer cells from chemotherapy -- and they demonstrate which medication can be used to render it inoperative. Their study published in the ...
Cancer Mar 05, 2012 | 5 / 5 (2) | 0 |